OncoSec Medical Inc. (OTCQB: ONCS), a company developing
its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will
present at seven events in May. The company’s itinerary includes a
number of prominent scientific and investment conferences,
culminating in a presentation at the 2014 ASCO Annual Meeting.
PEGS: The Essential Protein Engineering Summit
Robert Pierce, M.D., Chief Medical Officer, will present a
discussion titled, “Glass Half-Empty or Half-Full? Potential
Mechanisms of Non-Response to Immunomodulatory Antibodies” at the
10th Annual Protein and Antibody Engineering Summit (PEGS), on May
5th, at 11:10 a.m. EDT, at Seaport World Trade Center in Boston,
MA.
‘PEGS: The Essential Protein Engineering Summit’ will attract
over 1800 attendees to Boston’s lively seaport district to
participate in a variety of open forum discussions and
collaborative affairs. This year’s summit will feature 20
conferences and 15 short courses. Dr. Pierce’s discussion will be a
part of the Cambridge Healthtech Institute’s 4th Annual Antibodies
for Cancer Therapy conference. For more information, please visit
http://www.pegsummit.com
10th Annual EADO Congress: Advances in
Diagnosis and Treatment of Skin Tumors
Axel Hauschild, M.D., Ph.D., Melanoma Advisory Board Member,
will present at the 10th Annual European Association of
Dermato-Oncology (EADO) Congress, to be held May 7th – 10th, 2014,
in Vilnius, Lithuania.
EADO Congress is a stimulating and well-established annual
affair that attracts top clinicians and researchers from around the
world to share and review the most current data and practical
information in the field of skin cancer. International key opinion
leaders will present and report on the latest clinical trial
results and discuss promising new treatments during the plenary
lectures and symposia, and attendees will find the state of the art
in prevention, early detection, innovative diagnostic, imaging, and
treatment techniques for cutaneous malignancies. For more
information, please visit: http://www.eado2014.com
Boston Biotech: Cancer Advance New York
Punit Dhillon, President and CEO, will be part of a discussion
titled, “Cancer in 15 Years: Predictions,” at Boston Biotech Cancer
Advance New York, on May 14, 2014 at 4:40 p.m. EDT, at Apella, an
event space in Alexandria Center in New York City, NY.
Cancer Advances will bring together some of the most
distinguished cancer experts from academia and industry, alongside
biotech entrepreneurs, venture capitalists, buysiders, bankers and
analysts, to participate in a high-energy, uniquely interactive
meeting. Boston Biotech hosts exclusive thought-leader forums for
senior bio-pharma executives. Each conference is highly interactive
and meant to facilitate discussion, information sharing,
networking, and corporate development among healthcare industry
leaders. For more information, please visit:
http://bbbiotechconference.com/conference-details.php?id=23
American Society of Gene and Cell Therapy (ASGCT)
17th Annual Meeting
Richard Heller, Ph.D., Scientific Advisory Board Member, will
present a discussion titled, “Non-Viral Gene Transfer of pIL-12 for
the Treatment of Melanoma: Results from Phase I and II Clinical
Trials” at the ASGCT 17th Annual Meeting, to be held May 21-24,
2014 at the Marriott Wardman Park in Washington D.C.
The American Society of Gene and Cell Therapy’s Annual Meeting
is designed to bring together scientists, physicians, patient
advocates, and other stakeholders to facilitate the transformation
of medicine by incorporating the use of genetic and cellular
therapies to control and cure human disease. Dr. Heller’s
discussion will be part of Scientific Symposium 213: Physical Gene
& Cell Therapy and Vector Development, taking place in the
Delaware AB room on May 22, 2014 from 10:15 a.m. – 12:15 p.m. EDT.
For more information, please visit: http://www.asgct.org
Marcum MicroCap Conference
Punit Dhillon, President and CEO, will present a corporate
overview of the company at the 3rd Annual Marcum MicroCap
Conference, to be held at the Grand Hyatt New York in New York City
on May 29, 2014. The invitation-only event attracts top fund
managers and qualified high net worth investors, and will feature
presentations from CEO’s and CFO’s of promising high-growth
companies. For more information, please visit:
http://www.marcumllp.com/microcap
American Cancer Society Blossom Ball
Punit Dhillon, President and CEO, will provide the Key Note
address at the American Cancer Society’s Blossom Ball, to be held
at Southridge Estates in Sutter, CA, on May 31, 2014. OncoSec
Medical is proud to serve as Title Sponsor of this premier gala
event, which will feature a silent auction, a gourmet dinner
provided by New Hock Farm, and conclude in a night of dancing and
live entertainment by the band JumpStart. For more information,
please visit: http://main.acsevents.org
American Society of Clinical Oncology (ASCO) 50th
Annual Meeting
Adil Daud, M.D., Chief Clinical Strategist, will present an
abstract titled, “Systemic anti-tumor effect and clinical response
in a phase 2 trial of intratumoral electroporation of plasmid
interleukin-12 in patients with advanced melanoma” (ASCO Abstract
#9025), at the 2014 ASCO Annual Meeting, to be held May 30-June 3,
2014 at McCormick Place in Chicago, Illinois. The abstract, which
highlights unreleased data from the company’s Phase 2 study
investigating the use of ImmunoPulse in patients with metastatic
melanoma, will be part of the Poster Highlights Session: Melanoma
and Skin Cancers, taking place June 2, 2014. For more information,
please refer to the ASCO iPlanner:
https://iplanner.asco.org/AM2014
ASCO 2014 will bring together over 25,000 oncology professionals
from a wide range of specialties to explore this year’s theme –
“Science and Society.” Attendees will have access to cutting-edge
scientific presentations and comprehensive educational content that
reflect ASCO’s dedication to providing the highest-quality
resources in education, policy, the pioneering of clinical
research, and the advancement of care for patients with cancer. For
more information, please visit: http://www.asco.org
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical’s core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec’s clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma
(http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search).
As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination therapeutic approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
OncoSec Medical Inc.Investor Relations:Veronica Vallejo,
CFO855-662-6732investors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024